Sugi Predict

Sugi Predict / Compounds / SCHEMBL717168

SCHEMBL717168

SCHEMBL717168

CCCCCCCC(CCCCCCC)(CCCCCCC)C(=O)OCC

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.61
▸ CYP4A11 Q02928 2/20 0.61
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ MAPT P10636 1/20 0.59
▸ ATM Q13315 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ HTT P42858 1/20 0.50
▸ THRB P10828 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ CES2 O00748 1/20 0.42
▸ NAAA Q02083 1/20 0.41
▸ DGKA P23743 1/20 0.41
▸ GGPS1 O95749 1/20 0.41
▸ SMPD1 P17405 1/20 0.40
▸ FAAH O00519 2/20 0.40
▸ FDPS P14324 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718008 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL87652 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL169939 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL28984795 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL10871818 1.00 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL28462437 0.98 CYP4F2 (0.59) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL503887 0.94 CYP4F2 (0.56) CYP4F2CYP4A11MEN1KMT2AMAPT
Acetic Acid SCHEMBL8601641 0.94 MEN1 (0.58) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL6531912 0.94 CYP4F2 (0.56) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL369993 0.94 CYP4F2 (0.56) CYP4F2CYP4A11MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005619-A Process for producing heterocyclic compound 武田药品工业株式会社 2024-05-10 — — CN disclosed
US-20240148741-A1 FORMULATION FOR ORAL ADMINISTRATION, COMPRISING TRIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2024-05-09 — — US disclosed
CN-110753689-B Process for producing heterocyclic compound 武田药品工业株式会社 2024-01-26 — — CN disclosed
CN-117255680-A Formulations for oral administration containing triazine derivatives 盐野义制药株式会社 2023-12-19 — — CN disclosed
EP-4289432-A1 PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVE Shionogi & Co., Ltd (JP) 2023-12-13 — — EP disclosed
CN-116514734-A Process for producing triazine derivative and orally administered preparation containing triazine derivative 盐野义制药株式会社 2023-08-01 — — CN disclosed
US-20230226037-A1 PROLONGED ECTOPARASITE-CONTROLLING AGENT FOR ANIMAL MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) 2023-07-20 — — US disclosed
US-11696913-B2 Prolonged ectoparasite-controlling agent for animal MITSUI CHEMICALS AGRO, INC. (JP) 2023-07-11 — — US disclosed
US-11647666-B2 Organic electroluminescent element KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) 2023-05-09 — — US disclosed
CN-110692146-B Organic electroluminescent element, and display device or lighting device 学校法人关西学院（JP） 2023-01-13 — — CN disclosed
US-20050282864-A1 Indole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. 2005-12-22 — — US disclosed
CN-1217927-C Novel 1, 2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism AVENTIS PHARMA GMBH (DE) 2005-09-07 — — CN disclosed
US-20050085483-A1 Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-04-21 — — US disclosed
EP-1012164-B1 SERINE PROTEASE INHIBITORS AKZO NOBEL NV (NL) 2004-09-22 — — EP disclosed
CN-1483021-A Novel 1, 2-diphenyl azetidinones, process for their preparation, medicaments containing them and their use in the treatment of disorders of lipid metabolism ���ĵ�˹ҩ��¹����޹�˾ 2004-03-17 — — CN disclosed
US-6218365-B1 FOR TREATING OR PREVENTING A THROMBIN-RELATED DISEASE AKZO NOBEL N.V. (NL) 2001-04-17 — — US disclosed
EP-1012164-A1 SERINE PROTEASE INHIBITORS Akzo Nobel N.V. (NL) 2000-06-28 — — EP disclosed
CN-1202902-A Thrombin inhibitors AKZO NOBEL NV (NL) 1998-12-23 — — CN disclosed
WO-1997031939-A1 SERINE PROTEASE INHIBITORS AKZO NOBEL N.V. (NL) 1997-09-04 — — WO disclosed
US-5463062-A Inhibitors of glucose-6-phosphatase system HOECHST AKTIENGESELLSCHAFT (DE) 1995-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696913-B2 Prolonged ectoparasite-controlling agent for animal MTX1, ENPP1, CAT CYP4F2 233/4885CYP4A11 284/4885MEN1 686/4885
US-20230226037-A1 PROLONGED ECTOPARASITE-CONTROLLING AGENT FOR ANIMAL MTX1, ENPP1, CAT CYP4F2 233/4885CYP4A11 284/4885MEN1 686/4885
US-20050282864-A1 Indole derivatives as H3 inverse agonists HRH3, HRH4, ADRB1 CYP4F2 1822/4885CYP4A11 709/4885MEN1 2622/4885
US-20050085483-A1 Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments DPYD, NUDT1, NT5C2 CYP4F2 488/4885CYP4A11 631/4885MEN1 1919/4885
US-20240148741-A1 FORMULATION FOR ORAL ADMINISTRATION, COMPRISING TRIAZINE DERIVATIVE MKI67, IL5, IL15 CYP4F2 298/4885CYP4A11 217/4885MEN1 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.